CareDx, Inc
NASDAQ:CDNAMedical - Diagnostics & Research
+$1.19 today
- Market cap
- $3.91B
- Beta
- 2.48
- P/E (TTM)
- -154.0
- EPS (TTM)
- -$0.16
Volume 0.54M
Average 0.74M
CDNA Capital Expenditures
Cash spent on property, plant, equipment, and other long-term assets.
CareDx, IncNASDAQ: CDNA
Capital Expenditures · Q2 FY2026 · quarter ended Jun 2026
Capital expenditures growth accelerates
Q2 FY2026 capital expenditures of $1.86M (cash outflow) rose 84.5% year over year, ahead of the +47.4% change in trailing-twelve-month capital expenditures. Sequentially, it fell 51.3% from the prior quarter. Over 3 fiscal years it compounded at -37.6% a year.
Context
- Capital expenditures amounted to 1.6% of revenue in FY2025, down 0.4 pp from a year earlier.
- Capital expenditures grew in size in 0 of the last 3 fiscal years.
- FY2025 was the smallest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +84.5% holds above the trailing-twelve-month pace of +47.4%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Capital Expenditures history
USD · from the cash flow
- Latest · FY2025
- (5.91M) USD
- Year-over-year change
- +8.8%
| Period | Period end | Capital Expenditures | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (5.91M) | +8.8% |
| FY2024 | 2024-12-31 | (6.48M) | +29.8% |
| FY2023 | 2023-12-31 | (9.24M) | +62.0% |
| FY2022 | 2022-12-31 | (24.33M) | -20.1% |
| FY2021 | 2021-12-31 | (20.26M) | — |
Capital Expenditures vs competitors
How CDNA compares with its peers on the latest reported figures
- CDNA's LTM Jun 2026 capital expenditures of $8.61M is the smallest of the 8 companies compared; the peer median is $23.2M.
- Its year-over-year change of +47.4% is the 3rd highest of 7, against a peer median of +26.0%.
- Capital expenditures amounts to 1.9% of revenue for CDNA, versus a peer median of 5.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $206.77M | +15.7% | +10.4% | 9.8% | |
| LTM Jun 2026 | $156.54M | +90.6% | +30.6% | 5.8% | |
WGSGeneDx Holdings Corp. | LTM Jun 2026 | $27.09M | +122.1% | +9.9% | 6.0% |
| LTM Mar 2026 | $23.2M | -21.1% | -29.9% | 2.8% | |
| LTM Mar 2026 | $23.06M | -43.7% | +6.3% | 7.2% | |
| LTM Jun 2026 | $12.93M | +36.2% | +4.2% | 2.3% | |
BLLNBillionToOne, Inc. | LTM Jun 2026 | $12.18M | — | — | 3.1% |
| LTM Jun 2026 | $8.61M | +47.4% | -37.6% | 1.9% | |
| Peer median (excluding CDNA) | $23.2M | +26.0% | +8.1% | 5.8% | |
Competitors are the stored peer set for CDNA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (30.66M) | (76.61M) | (190.28M) | 52.55M | (21.35M) |
| Depreciation & Amortization | 11.89M | 16.01M | 19.82M | 19.76M | 20.42M |
| Deferred Income Tax | 0 | 0 | 566K | (187K) | 17K |
| Stock-Based Compensation | 36.08M | 46.55M | 49.09M | 66.41M | 34.86M |
| Change in Working Capital | (40.97M) | (14.22M) | 106.03M | (102.31M) | 3.81M |
| Accounts Receivables | (24.42M) | (6.66M) | 16.02M | (13.74M) | 22.52M |
| Inventory | (6.93M) | (2.86M) | 54K | (1.02M) | (4.96M) |
| Accounts Payables | 1.79M | (2.05M) | 2.9M | (5.11M) | 808K |
| Other Working Capital | (11.42M) | (2.64M) | 87.06M | (82.44M) | (14.56M) |
| Other Non-Cash Items | 4.37M | 3.03M | (3.61M) | 1.83M | 4.28M |
| Operating Cash Flow | (19.29M) | (25.24M) | (18.39M) | 38.05M | 42.03M |
| Capital Expenditures | (20.26M) | (24.33M) | (9.24M) | (6.48M) | (5.91M) |
| Acquisitions (Net) | (15.43M) | (610K) | (6.68M) | 0 | 0 |
| Purchases of Investments | (5.5M) | (315.15M) | (201.17M) | (160.29M) | (145.93M) |
| Sales of Investments | 88.91M | 111.59M | 256.04M | 166.92M | 154.67M |
| Other Investing Activities | 0 | 0 | 1.5M | (634K) | 0 |
| Investing Cash Flow | 47.71M | (228.5M) | 40.45M | (483K) | 2.16M |
| Debt Repayment | (66K) | 0 | 0 | 0 | 0 |
| Common Stock Issued | 188.86M | 0 | 0 | 0 | 8M |
| Common Stock Repurchased | 0 | (642K) | (27.54M) | (522K) | (87.77M) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (3.15M) | (3.89M) | (2.07M) | (5.08M) | (13.62M) |
| Financing Cash Flow | 185.64M | (4.54M) | (29.61M) | (5.61M) | (93.39M) |
| Effect of Forex Changes | (303K) | 23K | (112K) | 532K | (90K) |
| Net Change in Cash | 213.76M | (258.25M) | (7.66M) | 32.49M | (49.29M) |
| Free Cash Flow | (39.55M) | (49.57M) | (27.63M) | 31.56M | 36.12M |
CareDx, Inc
NASDAQ:CDNA
Intrinsic Alpha fair value
Locked
Current Price
$74.44
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.